We are live on ! Find out more
BBH icon

VanEck Biotech ETF

106 hedge funds and large institutions have $109M invested in VanEck Biotech ETF in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 39 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

8% more funds holding

Funds holding: 98106 (+8)

4.88% less ownership

Funds ownership: 34.84%29.97% (-4.9%)

6% less capital invested

Capital invested by funds: $115M → $109M (-$6.74M)

67% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 39

69% less call options, than puts

Call options by funds: $232K | Put options by funds: $746K

Holders
106
Holders Change
+8
Holders Change %
+8.16%
% of All Funds
1.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
13
Reduced
39
Closed
3
Calls
$232K
Puts
$746K
Net Calls
-$514K
Net Calls Change
-$146K
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$18.1M -$110K -673 -0.6%
MIM
2
Miller Investment Management
Pennsylvania
$13.4M -$110K -674 -0.8%
Raymond James Financial
3
Raymond James Financial
Florida
$11.6M +$305K +1,869 +3%
Bank of America
4
Bank of America
North Carolina
$7.03M -$1.63M -10,022 -19%
Morgan Stanley
5
Morgan Stanley
New York
$5.25M +$56.9K +349 +1%
Wells Fargo
6
Wells Fargo
California
$4.64M +$88.4K +542 +2%
LPL Financial
7
LPL Financial
California
$3.22M -$462K -2,833 -13%
UBS Group
8
UBS Group
Switzerland
$3.12M -$395K -2,422 -11%
BFG
9
Bleakley Financial Group
New Jersey
$2.9M -$237K -1,451 -8%
CCA
10
Conservest Capital Advisors
Pennsylvania
$2.53M -$75.3K -462 -3%
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$2.38M -$753K -4,621 -24%
PPWM
12
Paragon Private Wealth Management
Kentucky
$2.22M +$1.51M +9,254 +224%
Rockefeller Capital Management
13
Rockefeller Capital Management
New York
$1.97M +$8.15K +50 +0.4%
BRM
14
Boston Research & Management
Massachusetts
$1.73M -$59.7K -366 -3%
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
$1.68M -$103K -629 -6%
AGC
16
Aspen Grove Capital
Colorado
$1.65M
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$1.55M +$719K +4,411 +89%
LJAC
18
L.J. Altfest & Co
New York
$1.47M +$52.5K +322 +4%
IFWM
19
Institute for Wealth Management
Colorado
$1.24M -$14.2K -87 -1%
PGFC
20
Peapack-Gladstone Financial Corp
New Jersey
$1.19M -$37.5K -230 -3%
Stifel Financial
21
Stifel Financial
Missouri
$1.1M -$20.7K -127 -2%
HighTower Advisors
22
HighTower Advisors
Illinois
$1.09M -$494K -3,030 -31%
Ameriprise
23
Ameriprise
Minnesota
$1.08M -$151K -929 -13%
Cerity Partners
24
Cerity Partners
New York
$960K
Wealthfront Advisers
25
Wealthfront Advisers
California
$893K -$90.3K -554 -9%

BBH Hedge Fund Activity: Q3 2025 in Review

106 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2025, worth a combined $109M — down 5.8% from $115M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new BBH positions and 3 closed out — a net gain of 10 holders — while 13 added to existing stakes and 39 trimmed.

The largest buyer was Paragon Private Wealth Management, adding an estimated $1.51M. The largest seller was TD Waterhouse Canada, cutting an estimated $10.5M.

  • 106 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2025, up from 98 in Q2 2025.
  • Funds reported $109M of VanEck Biotech ETF stock for Q3 2025, down 5.8% quarter-over-quarter.
  • 13 funds opened new VanEck Biotech ETF positions in Q3 2025 and 3 closed out, a net change of +10 holders.
  • The largest VanEck Biotech ETF buyer in Q3 2025 was Paragon Private Wealth Management, an estimated $1.51M added.
  • The largest VanEck Biotech ETF seller in Q3 2025 was TD Waterhouse Canada, an estimated $10.5M sold.

Based on aggregated 13F filings for Q3 2025.